PMID- 22017433
OWN - NLM
STAT- MEDLINE
DCOM- 20120209
LR  - 20171116
IS  - 1600-065X (Electronic)
IS  - 0105-2896 (Linking)
VI  - 244
IP  - 1
DP  - 2011 Nov
TI  - LTbetaR and CD40: working together in dendritic cells to optimize immune responses.
PG  - 85-98
LID - 10.1111/j.1600-065X.2011.01056.x [doi]
AB  - Generating an immune response tailored to destroy an infecting organism while 
      limiting bystander damage involves guiding T-cell activation using a variety of 
      cues taken from the immunogen (antigen type, dose, and persistence, accompanying 
      danger signals) as well as the host (tissue environment, T-cell frequency, and 
      affinity for antigen). Dendritic cells (DCs) serve as translators of much of this 
      information and are critically required for effective pathogen and tumor 
      clearance. Moreover, dysregulation of DC activation can lead to autoimmunity. 
      Inhibition of the lymphotoxin (LT) and CD40 pathways has been shown to be 
      effective at quieting inflammation in settings where DC-T-cell interactions are 
      key instigators of disease progression. In this review, we compare and contrast 
      the CD40 and LT pathways in the context of receptor/ligand expression, signal 
      transduction, and DC biology. We provide evidence that these two pathways play 
      complementary roles in DC cytokine secretion, thus indirectly shaping the nature 
      of the CD8(+) T-cell response to foreign antigen. Given the distinct role of 
      these pathways in the context of DC function, we propose that dual therapies 
      targeted at both the CD40 and LTbeta receptor may have therapeutic potential in 
      silencing DC-driven autoimmunity or in promoting tumor clearance.
CI  - (c) 2011 John Wiley & Sons A/S.
FAU - Gommerman, Jennifer L
AU  - Gommerman JL
AD  - Department of Immunology, University of Toronto, Toronto, ON, Canada. 
      jen.gommerman@utoronto.ca
FAU - Summers deLuca, Leslie
AU  - Summers deLuca L
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Immunol Rev
JT  - Immunological reviews
JID - 7702118
RN  - 0 (CD40 Antigens)
RN  - 0 (Interferon-alpha)
RN  - 0 (Lymphotoxin beta Receptor)
RN  - 77238-31-4 (Interferon-beta)
SB  - IM
MH  - Animals
MH  - Autoimmunity
MH  - B-Lymphocytes/immunology/metabolism
MH  - CD40 Antigens/genetics/*immunology/metabolism
MH  - CD8-Positive T-Lymphocytes/immunology/metabolism
MH  - Cell Communication/*immunology
MH  - Cell Transformation, Neoplastic/immunology
MH  - Dendritic Cells/*immunology/metabolism
MH  - Gene Expression
MH  - Humans
MH  - *Immunity, Innate
MH  - Inflammation/*immunology
MH  - Interferon-alpha/genetics/immunology/metabolism
MH  - Interferon-beta/genetics/immunology/metabolism
MH  - Lymphocyte Activation/immunology
MH  - Lymphotoxin beta Receptor/genetics/*immunology/metabolism
MH  - Mice
MH  - Mice, Knockout
MH  - Signal Transduction/*immunology
EDAT- 2011/10/25 06:00
MHDA- 2012/02/10 06:00
CRDT- 2011/10/25 06:00
PHST- 2011/10/25 06:00 [entrez]
PHST- 2011/10/25 06:00 [pubmed]
PHST- 2012/02/10 06:00 [medline]
AID - 10.1111/j.1600-065X.2011.01056.x [doi]
PST - ppublish
SO  - Immunol Rev. 2011 Nov;244(1):85-98. doi: 10.1111/j.1600-065X.2011.01056.x.